Brand Reference: Intrarosa
| Metric | Verified Benchmark | Source |
|---|---|---|
| Prasterone (Micronized Dehydroepiandrosterone) RxNorm Concept ID | 3143 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $7.4200 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $248.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $45.00 / mo (Direct TeleMed) | Direct Telehealth Formulary |
| Community Mean Out-of-Pocket Paid | $38.00 / mo | 14 Zero-PHI Verified Patient Logs |
Endogenous C19 delta-5 prohormone converted locally inside target tissues via 3-beta-HSD and 17-beta-HSD intracrine enzymes into tissue-specific estrogens and androgens without systemic serum spillover when applied locally or micro-dosed orally.
CMS National Average Drug Acquisition Cost (NADAC) tracking places Prasterone (Micronized Dehydroepiandrosterone) (Intrarosa, RxCUI 3143) at $7.4200 per unit, whereas walk-in chain pharmacies bill cash patients an average of $248.00 monthly—creating a 85% ($210.00/mo) wholesale arbitrage spread down to $38.00.
Systemic exposure to Prasterone (Micronized Dehydroepiandrosterone) reflects ~65% micronized oral / local mucosal absorption kinetics and sulfotransferase sult2a1 sulfation and 7-alpha-hydroxylation, sustaining receptor engagement across a 15–38 minutes free DHEA / 7–10 hours DHEA-S sulfate pool half-life window (2–4 weeks dhea-s restoration response profile).
Dosing protocols (6.5 mg intravaginal insert nightly (Intrarosa) or 10–25 mg micronized PO QAM) balance efficacy (83.00% patient satisfaction across 14 logs) against oily t-zone skin (14% of reports), local insert discharge (11% of reports), with strict avoidance in undiagnosed abnormal uterine bleeding; estrogen/androgen-sensitive neoplasia.
Across 14 verified cash-pay logs, Prasterone (Micronized Dehydroepiandrosterone) achieves a 83.00% Worth-It rating with out-of-pocket spend averaging $38.00/mo versus $248.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to TeleMed at 6.5 mg intravaginal insert nightly (Intrarosa) for Prasterone (Micronized Dehydroepiandrosterone); monthly out-of-pocket dropped to $33.44 compared with $248.00 retail.
Completed 10 weeks on Prasterone (Micronized Dehydroepiandrosterone) (10–25 mg micronized PO QAM). Zero notable side effects on steady dosing.
Consistent biomarker response on 6.5 mg intravaginal insert nightly (Intrarosa) Prasterone (Micronized Dehydroepiandrosterone) sourced via Cash Clinic ($44.08/mo cash pay without insurance prior authorization).